Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Protara Therapeutics, Inc. (NASDAQ:TARA) has been given an average rating of “Moderate Buy” by the seven brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $19.60.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Saturday, September 27th.

Protara Therapeutics Stock Down 1.0%

TARA opened at $4.82 on Wednesday. Protara Therapeutics has a 12-month low of $1.60 and a 12-month high of $10.48. The stock has a market cap of $185.96 million, a price-to-earnings ratio of -2.98 and a beta of 1.53. The business has a 50 day moving average of $3.42 and a 200-day moving average of $3.44.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. As a group, analysts expect that Protara Therapeutics will post -3.32 earnings per share for the current year.

Hedge Funds Weigh In On Protara Therapeutics

A number of large investors have recently made changes to their positions in TARA. Squarepoint Ops LLC bought a new position in shares of Protara Therapeutics during the fourth quarter worth approximately $110,000. Charles Schwab Investment Management Inc. bought a new position in shares of Protara Therapeutics during the first quarter worth approximately $64,000. American Century Companies Inc. bought a new position in shares of Protara Therapeutics during the first quarter worth approximately $154,000. Walleye Capital LLC increased its stake in shares of Protara Therapeutics by 3.9% during the first quarter. Walleye Capital LLC now owns 229,454 shares of the company’s stock worth $977,000 after purchasing an additional 8,640 shares during the period. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Protara Therapeutics during the first quarter worth approximately $320,000. Institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.